2006-03-01
Incidence and risk factors of open-angle glaucoma : the Rotterdam study
Publication
Publication
Incidentie en risicifactoren van open-kamerhoek glaucoom: het ERGO onderzoek
Abstract
Glaucoma is one of the poorest understood and defined eye diseases among those known since our era. Despite two millennia of writing about glaucoma, a straightforward and clear-cut definition is not available worldwide. In essence, glaucoma is an eye disease characterized by loss of retinal ganglion cells and their axons. Clinically, this loss becomes apparent by cupping, also called excavation, of the optic disc and concomitant visual field loss. There are many subgroups of glaucoma, separated by causes, genetics, or morphology, and within each group there may be tens of different glaucoma types. From the start, I would like to point out that this thesis focuses on primary open-angle glaucoma. This is glaucoma in which the persons have open angles in their anterior eye chamber, through which the intraocular fluid leaves the eye. Moreover, all causes of secondary glaucoma, such as inflammation, medication, and systemic disorders, should have been eliminated with a reasonable amount of certainty. Since open-angle glaucoma cases with pseudoexfoliation were not specifically excluded at baseline of the Rotterdam study, we prefer to refer to open-angle glaucoma instead of primary open-angle glaucoma although during follow-up, no pseudoexfoliation was observed.
| Additional Metadata | |
|---|---|
| , | |
| P.T.V.M. de Jong (Paulus) | |
| The work described in this PhD-thesis was conducted at the Department of Epidemiology & Biostatistics of the Erasmus MC, University Medical Center, Rotterdam, the Netherlands. The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The work in this thesis was supported by ZonMw (grant 2200.0035), The Hague. Foundations: Optimix, Amsterdam; NWO, The Hague; Physico Therapeutic Institute, Rotterdam; Blindenpenning, Amsterdam; Sint Laurens Institute, Rotterdam; Bevordering van Volkskracht, Rotterdam; Blindenhulp, The Hague; Rotterdamse Blindenbelangen Association, Rotterdam; OOG, The Hague; kfHein, Utrecht; Ooglijders, Rotterdam; Prins Bernhard Cultuurfonds, Amsterdam; Van Leeuwen Van Lignac, Rotterdam; Verhagen, Rotterdam; Netherlands Society for the Prevention of Blindness, Doorn; LSBS, Utrecht; and Elise Mathilde, Maarn. Unrestricted grants were obtained from Topcon Europe BV, Capelle aan de IJssel; Lameris Ootech BV, Nieuwegein; Carl Zeiss BV Nederland, Sliedrecht; Merck Sharp & Dohme, Haarlem; all in The Netherlands, and from Heidelberg Engineering, Dossenheim, Germany. The contributions of the general practitioners and pharmacists of the Ommoord district to the Rotterdam Study are greatly acknowledged. The publication of this thesis was financially supported by Alcon Nederland BV, Gorinchem; Allergan BV, Nieuwegein; Bausch&Lomb, Schiphoi-Rijk; Lameris Ootech BV, Nieuwegein; Landelijke Stichting voor Blinden en Slechtzienden, Utrecht; Novartis Pharma BV, Arnhem; Pfizer BV, Capelle aan den IJssel; Sensis: zorg, onderwijs en diensten voor slechtziende en blinde mensen (www.sensis.nl), Grave; Stichting voor Ooglijders, Rotterdam; Ursapharm Benelux BV, Helmond; Visio, Huizen. | |
| hdl.handle.net/1765/76913 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
de Voogd, S., & Hofman, A. (2006, March). Incidence and risk factors of open-angle glaucoma : the Rotterdam study. The work described in this PhD-thesis was conducted at the Department of Epidemiology & Biostatistics of the Erasmus MC, University Medical Center, Rotterdam, the Netherlands. The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The work in this thesis was supported by ZonMw (grant 2200.0035), The Hague. Foundations: Optimix, Amsterdam; NWO, The Hague; Physico Therapeutic Institute, Rotterdam; Blindenpenning, Amsterdam; Sint Laurens Institute, Rotterdam; Bevordering van Volkskracht, Rotterdam; Blindenhulp, The Hague; Rotterdamse Blindenbelangen Association, Rotterdam; OOG, The Hague; kfHein, Utrecht; Ooglijders, Rotterdam; Prins Bernhard Cultuurfonds, Amsterdam; Van Leeuwen Van Lignac, Rotterdam; Verhagen, Rotterdam; Netherlands Society for the Prevention of Blindness, Doorn; LSBS, Utrecht; and Elise Mathilde, Maarn. Unrestricted grants were obtained from Topcon Europe BV, Capelle aan de IJssel; Lameris Ootech BV, Nieuwegein; Carl Zeiss BV Nederland, Sliedrecht; Merck Sharp & Dohme, Haarlem; all in The Netherlands, and from Heidelberg Engineering, Dossenheim, Germany. The contributions of the general practitioners and pharmacists of the Ommoord district to the Rotterdam Study are greatly acknowledged. The publication of this thesis was financially supported by Alcon Nederland BV, Gorinchem; Allergan BV, Nieuwegein; Bausch&Lomb, Schiphoi-Rijk; Lameris Ootech BV, Nieuwegein; Landelijke Stichting voor Blinden en Slechtzienden, Utrecht; Novartis Pharma BV, Arnhem; Pfizer BV, Capelle aan den IJssel; Sensis: zorg, onderwijs en diensten voor slechtziende en blinde mensen (www.sensis.nl), Grave; Stichting voor Ooglijders, Rotterdam; Ursapharm Benelux BV, Helmond; Visio, Huizen. Retrieved from http://hdl.handle.net/1765/76913 |
|
